2.32MMarket Cap-15P/E (TTM)
0.2273High0.2184Low345.86KVolume0.2191Open0.2200Pre Close77.59KTurnover3.34%Turnover RatioLossP/E (Static)10.36MShares14.219952wk High0.31P/B2.32MFloat Cap0.217652wk Low--Dividend TTM10.35MShs Float221.0000Historical High--Div YieldTTM4.05%Amplitude0.0026Historical Low0.2240Avg Price1Lot Size
SciSparc Stock Forum
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
SciSparc (Nasdaq: SPRC) has received FDA approval to proceed with its Phase IIb clinical trials in the U.S. for SCI-110, a potential breakthrough treatment for Tourette Syndrome (TS) in adults. This approval comes just one month after the application submission, marking a significant milestone for the company. The trial will be conducted at th...
2 MINUTES AGO, 8:17 AM EDT
VIA GLOBENEWSWIRE
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
No comment yet